This suggests that our MO-MLPS would be used to evaluate the expression of immune checkpoint genes, and LUAD patients with high-risk score may benefit more from anti-PD-L1 or PD-1 immunotherapy through relieving immune cells from the suppressed tumor microenvironment. This evidence concerns the gene CD274 and neoplasm.